Here are 1-3 brief analogies to describe Evogene:

• The '3M' for biological innovation.
  (Like 3M applies core scientific R&D to create diverse products across many industries, Evogene applies computational biology and AI to discover and develop diverse biological solutions in agriculture, human health, and sustainable materials.)
• A 'Ginkgo Bioworks' focused on AI-driven computational discovery across diverse biological applications like agriculture, human health, and sustainable materials.
  (Similar to Ginkgo's platform approach to engineering biology, Evogene uses a powerful AI-driven computational platform to discover novel biological solutions for various sectors.)

• Trait Discovery & Development for Agriculture: Evogene provides services focused on discovering and developing superior genetic traits to enhance agricultural seeds for improved yield, resilience, and nutritional value.
• Agricultural Biologicals: Through its subsidiary Lavie Bio, Evogene develops and markets microbiome-based products aimed at improving crop health, enhancing yield, and protecting against pests and diseases.
• Sustainable Castor Bean Varieties: Evogene, via Casterra Ag, develops and commercializes genetically optimized castor bean varieties designed for sustainable industrial applications.
• Microbiome-based Therapeutics: Through its subsidiary Biomica, Evogene develops novel microbiome-based therapeutic drug candidates for the treatment of various human diseases.

Evogene (symbol: EVGN) operates primarily on a business-to-business (B2B) model, leveraging its AI-driven biological discovery platform to develop and license specialized products and technologies through its subsidiaries to other companies. Its major customers and partners include:

• Corteva Agriscience (Symbol: CTVA): A significant partner and investor in Evogene's subsidiary, Lavie Bio. Corteva and Lavie Bio have a strategic collaboration focused on developing and commercializing microbiome-based agriculture products, including bio-stimulants and bio-pesticides.
• Syngenta (Private Company): Evogene's subsidiary, Lavie Bio, has an agreement with Syngenta for the commercialization of its bio-fungicide products in certain regions.
• Leading Global Agrochemical Companies: Evogene's subsidiary, AgPlenus, focuses on discovering and developing novel sustainable solutions for crop protection (e.g., herbicides, insecticides, fungicides). Its business model involves partnering with and licensing its proprietary solutions to major global agrochemical companies for further development and commercialization. Specific names are often under confidentiality agreements until later stages.
• Pharmaceutical Companies: Evogene's subsidiary, Biomica, is engaged in the discovery and development of microbiome-based therapeutics for various medical conditions. Biomica's strategy involves collaborating with pharmaceutical companies for co-development, clinical trials, and ultimate commercialization of these novel drug candidates.
• Industrial Castor Growers and Processors: Evogene's subsidiary, Casterra Ag, develops and markets high-yield castor seed varieties optimized for sustainable agriculture and industrial applications. Its direct customers are large-scale agricultural growers and industrial processors who utilize castor oil and its derivatives in various industries.

Ofer Haviv, Chief Executive Officer, President & Director

Ofer Haviv has served as Evogene's President and Chief Executive Officer since December 2004, having initially joined the company in January 2002 as Chief Financial Officer. He played a key role in Evogene's spin-off from Compugen in 2002. Prior to Evogene, Mr. Haviv served as Director of Finance and Treasurer at Compugen for four years, during which time the company completed two private placements and an IPO on NASDAQ. He is a Certified Public Accountant and holds a BA in Accounting and Economics from Tel Aviv University.

Yaron Eldad, Chief Financial Officer

Yaron Eldad was appointed as Evogene's Chief Financial Officer in April 2022. He brings over 25 years of experience, having held various CFO positions in both public and private technology and biotechnology companies, including Yamba Group Int. Ltd. (2011-2021), Recoly NV (2008-2010), and e-Sim Ltd. (1998-2007). Mr. Eldad also serves on the board of directors and as chairman of the audit and compensation committees of B.O.S. Better Online Solutions Ltd. He holds a B.A. in Economics and Accounting from Ben-Gurion University of the Negev, an Executive MBA in Strategic Management from the Hebrew University of Jerusalem, and an M.A. in law from Bar-Ilan University.

Gabi Tarcic, Vice President - Product

Dr. Gabi Tarcic was appointed as Evogene's VP Product, effective September 22, 2024. She possesses extensive experience in research and development projects and as a senior executive. From 2012, Dr. Tarcic served in various roles at Fore Biotherapeutics (formerly NovellusDx Israel), where her most recent position was Chief Technology Officer. She holds a Ph.D. from The Weizmann Institute of Science.

Eyal Ronen, Executive Vice President, Business Development

Eyal Ronen was appointed as Executive Vice President of Business Development of Evogene in June 2022. He also served as Chief Executive Officer of Canonic, an Evogene subsidiary, during 2022 and was appointed CEO of Canonic effective January 1, 2023, in parallel to his role at Evogene. Mr. Ronen has over 20 years of extensive business development experience in the biotech sector, both in Israel and internationally. His prior experience includes roles such as Vice President of Business Development at TransAlgae, Vice President of Sales, Marketing, and Business Development at Fotonica Ltd., and CTO and Co-Founder at Seanovo. He holds a B.Sc. and M.Sc. in Agronomy from the Hebrew University of Jerusalem and an MBA from Haifa University.

Liat Wejgman, Vice President of Human Resources

Liat Wejgman (also known as Liat Foigel Wejgman) has served as Evogene's Vice President of Human Resources since 2022.

• The rapid advancement and increasing commoditization of generative artificial intelligence (AI) and computational biology tools by tech giants and open-source initiatives. This trend threatens to diminish the proprietary advantage of Evogene's Computational Predictive Biology (CPB) platform, making advanced biological design capabilities more widely accessible and potentially reducing the uniqueness and value proposition of Evogene's offerings.
• Increasing vertical integration and the development of sophisticated in-house computational biology and AI capabilities by major agricultural and pharmaceutical companies. This trend could lead to fewer partnership and licensing opportunities for Evogene, as potential clients build self-sufficiency, thereby limiting Evogene's pathways for commercializing its designed biological products.

Evogene (EVGN) operates in several life science industries, leveraging its Computational Predictive Biology (CPB) platform. The addressable markets for its main products and services include:

• Agriculture:
  • Bio-stimulants for spring wheat: approximately 25 million acres.
  • Bio-stimulants for corn: 120 million acres.
  • Bio-pesticides for fruit rots (fruits and vegetables): target market exceeding $200 million in chemical usage.
  • Bio-pesticides for Downey Mildew (fruits and vegetables): target market exceeding $350 million in chemical usage.
  • Bio-pesticides for seedling disease (corn and soy): target market exceeding $500 million.
  • Bio-insecticides for corn and soy: target market exceeding $1.5 billion in existing traits and chemicals.
  • The global agrochemicals market, which includes pesticides and fertilizers, was estimated at US$245.4 billion in 2024 and is projected to grow to USD 364.56 billion by 2035, at a Compound Annual Growth Rate (CAGR) of 3.87% during the forecast period 2025-2035. North America is expected to generate the highest demand, while Asia Pacific is anticipated to show the fastest growth.
• Human Health:
  • Medical Cannabis: The medical cannabis market size is expected to reach $25.6 billion globally by 2024.
  • Microbiome Therapeutics: The global microbiome therapeutics market size was valued at USD 187.13 million in 2024 and is projected to increase to approximately USD 3,405.99 million by 2034, growing at a CAGR of 33.67% from 2025 to 2034. The U.S. microbiome therapeutics market was estimated at USD 72.44 million in 2024 and is projected to reach around USD 1,340.34 million by 2034.

Evogene (EVGN) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

1. Expansion and Monetization of ChemPass AI in Drug Discovery: Evogene's strategic focus has shifted to enhancing and leveraging its ChemPass AI platform for AI-powered small molecule discovery in the pharmaceutical industry. The collaboration with Google Cloud to develop a generative AI foundation model for novel small molecule de novo design is a significant driver, aiming to accelerate drug discovery, reduce costs, and improve the success rate of identifying promising drug candidates across pharmaceuticals, agriculture, and other life-science industries. This initiative is expected to unlock new revenue streams through partnerships in the pharmaceutical sector.
2. Growth in Casterra's Seed Sales: Casterra, an Evogene subsidiary, has consistently been highlighted as a primary driver of recent and anticipated revenue growth. Reports indicate a significant increase in Casterra's seed sales, with the company successfully addressing seed production bottlenecks and delivering substantial quantities of castor seeds. This growth is expected to continue contributing to Evogene's overall revenue.
3. Strategic Partnerships and Collaborations utilizing AI Tech-Engines: Beyond the Google Cloud collaboration, Evogene's business model relies on strategic partnerships and collaborations for product development through its various AI tech-engines (ChemPass AI, MicroBoost AI, and GeneRator AI). These partnerships, which historically included major industry players like Corteva and Bayer, are crucial for commercializing innovative products and are expected to continue driving revenue through licensing agreements, milestone payments, and joint ventures in diverse life science sectors.
4. Value Generation from Remaining Subsidiaries: While Evogene has undergone restructuring and asset sales (e.g., Lavie Bio), the company emphasizes generating value and cash flow from its remaining subsidiaries, such as Biomica (focused on human microbiome therapeutics) and AgPlenus (developing next-generation ag chemicals). The diversified product pipelines within these independently managed subsidiaries, which utilize Evogene's computational biology platform, are anticipated to contribute to future revenue through their respective commercialization efforts and strategic alliances.

Share Issuance

• Evogene completed a fundraising in August 2024, raising $5.5 million in gross proceeds through the issuance of ordinary shares and two sets of warrants.
• One-time expenses of approximately $1.5 million in 2024 were related to Evogene's fundraising activities.

Capital Expenditures

• Evogene's capital expenditures were approximately $0.8 million in fiscal year 2023, $1.2 million in 2022, and $0.8 million in 2021.
• These capital expenditures primarily consisted of investments in property, plant, and equipment.
• For fiscal year 2024, Evogene anticipated capital expenditures would include payments for maintenance and improvements of its facilities in Israel.